Acellular Dermal Matrices: The New Standard In Breast Reconstruction

Recent advances in breast cancer surgical techniques, such as the advent of nipple-sparing mastectomy, along with growing physician acceptance of new biomaterials capable of improving outcomes following implant-based breast reconstruction, are making mastectomy and reconstruction surgery a more attractive treatment option for many breast cancer patients and will help drive strong growth in the US breast reconstruction market in the years ahead.

Roughly 250,000 American women undergo mastectomies each year following a diagnosis of invasive breast cancer, but only about one-third of eligible patients undergo reconstruction to restore breast shape, appearance, and size. However, recent trends suggest this situation is changing. Advances in breast reconstruction techniques and the introduction of new device and biomaterials technologies have made reconstruction following mastectomy a more cosmetically appealing procedure. This change, coupled with an ongoing, patient-driven shift away from breast-conserving surgery and back toward mastectomy, should drive strong growth in the US breast reconstruction market in the years ahead. (See Also see "The Evolving World Of Breast Cancer Management" - Medtech Insight, 6 July, 2012..)

In addition, the US reimbursement picture is also improving. Since 1998, health plans that offer breast cancer coverage have been...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Surgical Procedures

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By 

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

Bone Surgery Startup Surgify Medical Raises $7.9m

 

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

More from Surgery